Vesiflo

Vesiflo is a private, commercial-stage medical device company addressing a significant unmet need in female urology: chronic urinary retention. Its core product, the inFlow device, is an FDA-cleared, disposable intraurethral valve-pump that offers an alternative to intermittent self-catheterization, aiming to improve quality of life and reduce urinary tract infections. The company is augmenting its hardware with a digital health initiative, the Guardian Program, to enable remote patient monitoring and create a clinical data ecosystem. Operating from Massachusetts, Vesiflo targets a substantial patient population that has historically had limited treatment options.

Intraurethral valve-pump device combined with a developing remote patient monitoring and clinical information system (Guardian Program).

Competes primarily with manufacturers of intermittent and indwelling catheters (e.g., Coloplast, Hollister, BD). As a novel device, it faces limited direct competition but must displace established catheter use. Potential future competitors could include other novel bladder evacuation devices or advanced neuromodulation therapies.